The PharmFIT Study for Colorectal Cancer Screening
The PharmFIT Study is looking at a new way to help people get screened for colorectal cancer. This study tests an intervention called PharmFIT, which uses pharmacies to help patients who are not up-to-date on their screening. PharmFIT involves sending you reminders, distributing screening kits (FITs), and helping you understand your results. The study aims to see if PharmFIT can increase screening rates. Researchers will also look at how well the program works and its costs. This study is currently unclear on its recruitment status and is open to clinic and pharmacy staff aged 18 to 99 years old.
- Study design
- This is a randomized controlled trial planning to enroll 1500 participants. Patients will be assigned by chance to either receive usual care or the PharmFIT intervention.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure outcomes like service penetration, appropriateness, and acceptability of the PharmFIT intervention at 6 months after enrollment or randomization.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The PharmFIT Study
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Alison T Brenner, PhD MPH · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill
- Parth D Shah, PharmD PhD · PRINCIPAL_INVESTIGATOR · Fred Hutchinson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Service Penetration (Effectiveness)6-months post randomization
Receipt of any USPSTF guideline recommended CRC screening (FIT, FIT-DNA, sigmoidoscopy, colonoscopy, CT colonography, or barium enema), using a yes \["1"\] vs. no \["0"\] dichotomous outcome in the 6 months following randomization.
- Appropriateness of the PharmFIT intervention6-months post enrollment
Perceptions that PharmFIT is agreeable, palatable, or satisfactory.
- Acceptability of the PharmFIT intervention6-months post enrollment
Perceptions that PharmFIT is relevant to, fits or is compatible with a given practice site, provider, or patient.
- Feasibility of the PharmFIT intervention6-months post enrollment
Extent to which PharmFIT was successfully implemented and used within the clinics and pharmacies, measured by the Implementation Outcomes Questionnaire (IOQ) Feasibility Subscale.
- Fidelity to the PharmFIT interventionBaseline, 6-months post enrollment
PharmFIT delivered as intended; adherence; integrity; quality of PharmFIT intervention delivery, measured using the study's REDCap tracking database (e.g., patient communications delivered, FIT kits distributed, results reports, etc.).
- Cost of the PharmFIT interventionThrough study completion, up to 12 months after PharmFIT intervention implementation
Incremental cost of each additional patient screened in the intervention arm compared to usual care. Comparison of the programmatic costs incurred, and number of subjects screened in Arm 1(trial PharmFIT) compared to Arm 2 (usual care), measured as cost of intervention minus the cost of usual care, divided by the number screened in Arm 1 minus the number screened in Arm 2. Intervention costs will be assessed using periodic episodes of direct observation of PharmFIT outreach activities, time logs maintained by the intervention team, and assembly of administrative data capturing non-personnel/non-labor expenditures, such as costs associated with materials printing, FIT processing, and mailing costs. Usual care costs will be estimated using data collected from collaborative process flow diagramming sessions.